Closure of ATP-sensitive K+ channels (KATP channels) is a key step in glucose-stimulated insulin secretion. The precise mechanism(s) by which glucose metabolism regulates KATP channel activity, however, remains controversial. It is widely believed that the principal determinants are the intracellular concentrations of the metabolic ligands, ATP and ADP, which have opposing actions on KATP channels, with ATP closing and MgADP opening the channel. However, the sensitivity of the channel to these nucleotides in the intact cell, and their relative contribution to the regulation of channel activity, remains unclear. The precise role of phosphoinositides and long-chain acyl-CoA esters, which are capable of modulating the channel ATP sensitivity, is also uncertain. Furthermore, it is still a matter of debate whether it is changes in the concentration of ATP, of MgADP, or of other agents, which couples glucose metabolism to KATP channel activity. In this article, we review current knowledge of the metabolic regulation of the KATP channel and provide evidence that MgADP (or MgATP hydrolysis), acting at the regulatory subunit of the channel, shifts the ATP concentration-response curve into a range in which the channel pore can respond to dynamic changes in cytosolic ATP. This metabolic pas de deux orchestrates the pivotal role of ATP in metabolic regulation of the KATP channel.
The ATP-sensitive K+ channel (KATP channel) activity plays a crucial role in glucose-stimulated insulin secretion by coupling β-cell metabolism to calcium entry (1). Insulin secretion is triggered by an increase in the cytoplasmic Ca2+ concentration, which results from Ca2+ influx through voltage-gated Ca2+ channels in the plasma membrane. Opening of these channels is controlled by the membrane potential, which, in turn, is determined largely by the activity of the KATP channel (Fig. 1). At substimulatory glucose concentrations, KATP channels are open, and K+ efflux through these channels serves to maintain the resting membrane potential at a hyperpolarized level of around −70 mV. A small inward current (which has not yet been identified) must also be present because the resting potential is less negative than the K-equilibrium potential. Elevation of the blood glucose concentration increases glucose uptake and metabolism by the β-cell, resulting in closure of the KATP channels. The reduction in K+ efflux means that the contribution of the inward current to the membrane potential increases and the membrane depolarizes. If this depolarization is sufficient, voltage-gated Ca2+ channels open, triggering electrical activity, Ca2+ influx, and insulin secretion. Closure of KATP channels therefore initiates insulin release, while KATP channel opening inhibits secretion.
As might be expected, drugs that inhibit KATP channels, like sulfonylureas, stimulate insulin secretion even in the absence of glucose, whereas drugs that open KATP channels (e.g., diazoxide) reduce insulin secretion even in the presence of glucose (2). Furthermore, loss-of-function mutations in KATP channel genes result in congenital hyper-insulinism of infancy, a serious disorder characterized by excessive and unregulated insulin secretion (3,4). In contrast, gain-of-function mutations in the pore-forming subunit of the channel impair insulin secretion and produce permanent neonatal diabetes (5). Defective metabolic regulation of the KATP channel, as a consequence of impaired metabolism, also results in diabetes (3,6,7).
MOLECULAR BIOLOGY OF THE KATP CHANNEL
Opening and closing of the KATP channel is influenced by the intracellular concentrations of nucleotides (particularly ATP and ADP [8]), lipids such as phosphatidylinositides (9,10), and long-chain acyl-CoA esters (11–13). Our understanding of how they exert their functional effects has been illuminated by an increasing knowledge of the molecular structure of the KATP channel.
The β-cell KATP channel is an octameric complex of two different types of protein subunit that coassemble in a 4:4 stochiometry. The pore is a tetramer of inwardly rectifying K+ channel (Kir6.2) subunits (14,15). Although all four subunits possess a binding site for ATP, ligand binding to a single Kir6.2 subunit is sufficient to close the channel (16). Each Kir6.2 subunit is associated with a regulatory sulfonylurea receptor (SUR)-1 subunit, which endows the channel with sensitivity to drugs such as sulfonylureas and K+ channel openers, as well as to the stimulatory action of MgADP (17). SUR1 is a member of the ATP-binding cassette (ABC) transporter family, and like other ABC proteins, it has two cytosolic nucleotide-binding domains (NBDs). Interaction of Mg-nucleotides (e.g., MgATP, MgADP) with the NBDs leads to opening of the channel (18–21). The nucleotide regulation of the KATP channel is therefore complex, as channel activity is inhibited by nucleotide binding to Kir6.2 and activated by Mg-nucleotide interaction with SUR1.
Much of the published literature states that changes in the ATP/ADP ratio regulate KATP channel activity. It is worth emphasizing, however, that this idea is misleading, as it is the absolute concentrations of ATP and ADP that are critical. Studies on inside-out patches demonstrate very clearly that for the same ATP/ADP ratio, high concentrations of ATP and ADP result in channel inhibition, whereas low concentrations of nucleotides support channel activity (8). This is a reflection of the fact that nucleotides exert both inhibitory and stimulatory effects on channel activity, and that the inhibitory action of ADP dominates at concentrations >1 mmol/l (8).
Properties of the nucleotide-binding sites on Kir6.2 and SUR1
Both Kir6.2 and SUR1 subunits are required to form a functional channel. However, truncation of the last 26–36 amino acids from Kir6.2 (Kir6.2ΔC) allows this subunit to reach the surface membrane in the absence of SUR (18). This construct provides a useful tool to dissect the effects of nucleotides on Kir6.2 and SUR1. The discovery that Kir6.2ΔC channels are inhibited by ATP, for example, revealed that ATP (and ADP) interact with Kir6.2 to cause channel closure (18,22). Site-directed mutagenesis has identified a number of residues in Kir6.2 that, when mutated, reduce the channel ATP sensitivity (22–24), and photoaffinity labeling with radiolabeled ATP analogs confirmed that Kir6.2 indeed binds ATP (25,26). Nucleotide binding does not require Mg2+, is strongly selective for the adenine base, and both ATP and ADP can mediate channel inhibition (22,27).
There is good evidence that Mg nucleotides stimulate KATP channel activity via interaction with SUR1. First, MgADP only stimulates KATP channels that contain SUR subunits: indeed, when Kir6.2ΔC is expressed in the absence of SUR1, MgADP blocks channel activity (18). This is because ADP also interacts with Kir6.2 to produce channel inhibition (22). Because Mg2+ is required for nucleotide binding to SUR1, ADP also blocks the channel in the absence of the cation. Second, mutations within the NBDs of SUR1 abolish the stimulatory effects of Mg nucleotides and unmask their inhibitory action on Kir6.2 (19,21).
In most ABC transporters, MgATP is the major ligand, and its hydrolysis to MgADP provides the energy required for substrate transport. Because ATP produces a potent block of the KATP channel via Kir6.2, the role of MgATP at the NBDs of SUR1 was investigated by coexpressing SUR1 with an ATP-insensitive pore mutant, Kir6.2-R50G (27). These channels were stimulated by MgATP, an effect that was abolished by mutations within the NBDs of SUR1. Thus, like MgADP, MgATP stimulates KATP channel activity by interaction with SUR1. It seems probable, however, that MgATP must be hydrolyzed to MgADP before it is able to enhance KATP channel activity, although this has only been shown explicitly for Kir6.2/SUR2A (the cardiac type of KATP channel) to date (28).
Photoaffinity labeling with 8-azido-[32P]ATP has been used to explore the nucleotide-binding properties of the NBDs of SUR1 (29). These studies showed that NBD1 of SUR1 binds 8-azido-ATP strongly in a Mg2+-independent manner, and that NBD2 binds 8-azido-ATP in a Mg2+-dependent manner. Because KATP channels are activated by ADP only in the presence of Mg2+ (20), this suggests that NBD2 is primarily responsible for channel activation by MgADP. NBD1 binds both ATP and ADP more tightly than NBD2 (as measured by their ability to displace 8-azido-ATP); however, there was no significant difference in the ability of NBD2 to bind ATP or ADP (29). The NBDs also differ in their ability to hydrolyze ATP. In particular, NBD2 of SUR1 appears to be more efficient at hydrolyzing ATP than NBD1 (29).
The ability of MgADP to stimulate KATP channel activity is also observed in the presence of ATP (20,21,30). Indeed, MgADP shifts the ATP concentration-inhibition curve to a higher intracellular ATP concentration ([ATP]i) (30). This suggests that the ATP sensitivity in the cell will be less than that measured in inside-out patches, because of the presence of MgADP. It also explains why the ATP sensitivity measured in inside-out patches is affected by the intracellular Mg2+ concentration ([Mg2+]i), the half-maximal inhibitory concentration (IC50) for channel inhibition by ATP being 6–10 μmol/l in Mg2+-free solution (27) and 10–30 μmol/l in the presence of Mg2+ (18,27,31). This difference presumably reflects ATP hydrolysis by the NBDs of SUR1 in the presence of Mg2+, which leads to occupation of NBD2 by MgADP (28) and causes a small amount of channel activation. Because the ability of MgADP to stimulate channel activity in excised patches is labile (32), the extent to which the ATP sensitivity is reduced is variable.
METABOLIC CHANGES IN ATP AND ADP CONCENTRATION
In pancreatic β-cells, an increase in plasma glucose concentration results in enhanced glycolytic and mitochondrial metabolism and the generation of ATP at the expense of ADP (33). More than 95% of ATP in the β-cell is produced by the mitochondria, and mitochondrially generated ATP is of primary importance for insulin release. Indeed, depletion of mitochondria from β-cells results in the complete loss of insulin secretion (34). Uncoupling proteins induce a mitochondrial proton leak that leads to impaired ATP production (35). Uncoupling protein (UCP)-2 is expressed in islets, and mice in which UCP2 was knocked out had higher islet ATP levels and increased insulin secretion; conversely, rodent islets overexpressing UCP2 had impaired insulin secretion (35).
A substantial fraction of the ATP (68%) and ADP (45%) within the β-cell is nondiffusible and contained in intracellular organelles (especially the insulin secretory granules) (36). Measurements of [ATP]i in purified rat β-cells suggest that [ATP]i is 2 pmol/103 cells in the absence of glucose and increases to >4 pmol/103 cells when glucose is raised to 10 mmol/l (37). Because the β-cell has a volume of roughly 1 pl, this suggests [ATP]i is ∼2 mmol/l at rest and increases to 4 mmol/l on glucose stimulation. These concentrations are in broad agreement with other studies in which β-cell [ATP]i is estimated to lie between 1 and 5 mmol/l, even during metabolic inhibition (38–40). However, a change in [ATP]i on exposure to glucose is not universally observed (39), and in some studies the increase in [ATP]i saturated at 10 mmol/l glucose (37). Total [ADP]i in purified β-cells was 750 μmol/l in the absence of glucose and fell to 250 μmol/l in response to 10 mmol/l glucose (37). Like in muscle, much ADP is probably bound to plasma proteins as the free concentrations are much lower—between 30 and 50 μmol/l (39). Glucose also causes a marked increase in phosphocreatine (PCr) and a fall in phosphate (41,42).
It is important to remember that an increase in metabolic flux consequent on an increased substrate supply need not necessarily be accompanied by an increase in [ATP]i (or fall in [ADP]i). This will depend on the relative rates of nucleotide generation and consumption and is discussed further below.
CAN CHANGES IN ADENINE NUCLEOTIDES REGULATE KATP CHANNEL ACTIVITY?
There is little doubt that changes in intracellular adenine nucleotide concentrations influence KATP channel activity in intact β-cells (43). Nutrients that elevate ATP, like glucose, produce KATP channel inhibition, as does supply of reducing equivalents directly to cytochrome C, the final step in the electron transport chain (44). Conversely, agents that inhibit mitochondrial metabolism and reduce ATP generation, like rotenone, DNP, and azide, activate KATP channels in pancreatic β-cells (45). Similarly, such agents open cloned β-cell KATP channels expressed in Xenopus oocytes or mammalian cell lines (18,31,46). Inhibition of the mitochondrial ATP/ADP translocase by bongkrekic acid, which prevents ATP export from the mitochondrion, also activates KATP channels (45).
But there are also considerable problems with the idea that ATP is the sole regulator of KATP channel activity (43). The principal argument against such a role for ATP is the clear discrepancy between the ATP sensitivity of the channel measured in the inside-out patch (IC50 = 10–30 μmol/l; [22]) and that in the intact cell (IC50 = 0.8 mmol/l; [47]). Furthermore, significant channel activity can be recorded from on-cell patches on β-cells exposed to glucose-free solutions (1), despite the fact that the [ATP]i measured under similar conditions suggests the channels should be almost completely closed (37). A number of different explanations can be put forward to account for this phenomenon. First, the submembrane ATP may not be the same as the bulk concentration, owing to the activity of membrane ATPases. Second, changes in [ATP]i could serve to mediate metabolic effects on channel activity if the ATP sensitivity is shifted, by another agent, into the range over which physiological changes in [ATP]i occur. Third, ATP could provide a tonic level of inhibition against which metabolically generated changes in some other substance regulate channel activity.
Theoretically, it is possible that ATP consumption by membrane ATPases (e.g., Na+/K+ ATPase) could lower the submembrane ATP concentration. In practice, however, this does not seem to account for the different ATP sensitivities of the KATP channel in excised patches and intact cells. Measurements using targeted luciferin indicate that [ATP] immediately beneath the β-cell plasma membrane is similar to that in the bulk cytosol, ∼1 mmol/l (38). Even when Kir6.2ΔC itself was used to sense submembrane ATP, values of ∼1.5 mmol/l in COSm6 cells and 5 mmol/l in oocytes were observed in control solution, and values of ∼1 mmol/l were observed following metabolic poisoning (46).
At least three agents are known to modulate the ATP sensitivity of the KATP channel: PIP2 (phosphatidylinositol-4,5-bisphosphate) and related phosphoinositides (PPIs) (9,10), long-chain acyl-CoA esters (LC-CoAs) (11–13), and MgADP (30). All decrease the ability of ATP to close the KATP channel. A key question is whether these agents simply shift the ATP concentration-inhibition curve to higher ATP concentrations, so that the channel is now sensitive to physiological changes in [ATP]i, or whether metabolically generated changes in PIP2, LC-CoA, or MgADP serve to couple metabolism to KATP channel inhibition.
REGULATION BY PHOSPHOLIPIDS
PPIs such as PIP2 and PIP3 interact with KATP channels to increase their open probability and reduce their ATP sensitivity. This has been shown by direct application of PPIs to KATP channels in excised patches (9,10). In addition, overexpression of phosphatidylinositol (PI) 5-kinase, which enhances PIP2 levels, reduces the ATP sensitivity of the KATP channel (48), whereas breakdown of PIP2 by phospholipase C increases the ATP sensitivity (49).
These effects are mediated principally through the Kir6.2 subunit, because Kir6.2ΔC expressed in the absence of SUR shows a reduced ATP sensitivity to applied PIP2 (10), and direct binding of PIP2 and other PPIs to Kir6.2ΔC has been demonstrated (26). The binding site for PPIs is distinct from that of ATP (50), but the two interact allosterically, with ATP reducing the binding of PPIs, and PPIs decreasing ATP binding (26). Two mechanisms have been proposed to account for the PPI-induced decrease in KATP channel ATP sensitivity (26): 1) compromised ATP binding and 2) changes in the intrinsic gating of the channel that indirectly influence ATP sensitivity (9) (briefly, PPIs reduce the time spent in a long closed state that is stabilized by ATP). Both are probably involved.
It appears that PPIs account, in part, for the difference in the ATP sensitivity of the KATP channel in the isolated patch and intact cell. Although in heterologous expression systems hormones and transmitters may modulate KATP channel activity via changes in PIP2 levels (49), this may not be the case in β-cells. For example, acetylcholine mediates PIP2 breakdown in β-cells but does not influence KATP currents (51). There is no evidence that glucose influences channel activity by modulating PIP2 levels. For example, wortmannin, which blocks PIP2 production by inhibiting PI 3-kinase, had no effect on glucose-stimulated insulin secretion, and glucose had no effect on either PI 3-kinase activity or PIP3 production (52).
REGULATION BY ACYL-CoAS
LC-CoAs enhance the open probability of the KATP channel and reduce its ATP sensitivity by interaction with the Kir6.2 subunit (11,12). They appear to bind to the same site as PIP2 (13). Interestingly, other Kir channels are not activated by LC-CoA, and this property is correlated with the uniquely low specificity of Kir6.2 for PPIs.
Increases in cytosolic LC-CoA in the β-cell can result from glucose metabolism and from free fatty acids (FFAs) delivered by the blood or released from endogenous lipid stores (rev. in 33). Because KATP channels are opened by LC-CoA, they cannot be involved in coupling glucose metabolism to channel inhibition, although a role in modulating β-cell electrical activity and, thus, insulin secretion at elevated glucose has been proposed (33). However, it has been suggested that LC-CoA may contribute to the reduced glucose sensitivity of the β-cell observed in obese diabetic individuals because chronic exposure to FFA leads to increased levels of LC-CoA within β-cells (11). These not only enhance KATP channel activity directly, they also decrease ATP production by, for example, inhibition of the ATP/ADP translocase and by upregulation of UCP2 (rev. in 35). LC-CoA may therefore exert a tonic effect on the KATP channel ATP sensitivity, shifting the concentration-inhibition curve into a range in which the channel opens more readily. As a consequence, glucose metabolism would not fully close KATP channels, and its ability to stimulate electrical activity, Ca2+ influx, and insulin secretion would be reduced.
REGULATION BY MgADP
Like PPIs and LC-CoAs, MgADP shifts the ATP dose-response curve to higher ATP concentrations (30,43). However, metabolically induced changes in MgADP have also been proposed to couple cell metabolism to channel activity. Nichols et al. (19) first reported that a mutation within NBD2 of SUR1 (G1479R) strongly reduced channel activation by MgADP. Importantly, KATP channels carrying this mutation were permanently closed even at low glucose levels and gave rise to congenital hyperinsulinism in humans. Subsequently, many other mutations within both SUR1 and Kir6.2 have been found to reduce MgADP activation and simultaneously prevent channel activation by metabolic inhibition (4,21). This raises the possibility that changes in MgADP couple cell metabolism to channel activity.
At first sight, this idea seems eminently reasonable. However, there are a number of problems. The first is that NBD2 of SUR1 binds ATP and ADP with similar affinities (see above), yet ATP is present at much greater concentration in the cell, even in the absence of glucose. This means that it is unlikely that metabolically induced changes in adenine nucleotides would lead to displacement of MgATP from SUR1 by MgADP.
One possibility is that an ATP hydrolysis cycle at NBD2 generates bound MgADP and that changes in cell metabolism influence KATP channel activity by modulating the length of time that NBD2 remains in the MgADP-bound (active) state (28). When metabolic activity is high, cytosolic ADP levels will be low, so that MgADP should dissociate rapidly from NBD2, causing channel activity to decrease. In contrast, when metabolic activity declines, the rise in [ADP]i will slow the off-rate of MgADP and promote channel opening. In this way, SUR1 could monitor changes in intracellular MgADP concentration. An alternative view, however, is that MgADP simply shifts the ATP dose-response curve into the physiological range and that changes in ATP constitute the means by which metabolism regulates KATP channel activity. Theoretical calculations suggest that 100 μmol/l ADP is sufficient to shift the ATP concentration-inhibition curve (8). It is also possible that both explanations are correct and that both SUR1 and Kir6.2 serve as metabolic sensors.
IS Kir6.2 ABLE TO SERVE AS A METABOLIC SENSOR?
To reexamine these two hypotheses, we tested the effects of metabolic poisoning on wild-type and mutant KATP channels. When wild-type Kir6.2 is coexpressed with SUR1 in Xenopus oocytes, KATP currents are almost undetectable due to inhibition by high [ATP]i. However, addition of 3 mmol/l azide, which blocks mitochondrial metabolism and lowers cytosolic ATP, produces a large increase in current (Fig. 2A and E) (31).
Each of the NBDs of SUR1 contains a number of highly conserved motifs that are involved in Mg-nucleotide binding and hydrolysis and in KATP channel activation by MgATP and MgADP. These include the Walker A, Walker B, and linker motifs. Mutation of the highly conserved lysine in the Walker A motif of NBD1 (K719) or NBD2 (K1384) abrogates ATP binding (53) and abolishes the ability of MgADP or MgATP to stimulate channel activity (20). Indeed, MgADP now blocks the channel because the inhibitory effect of the nucleotide (mediated via Kir6.2) is unmasked (20). As previously reported (20), when Kir6.2 is coexpressed with SUR1 in which both K719 and K1384 have been mutated (to alanine and methionine, respectively, which we refer to as SUR1-KAKM), azide is no longer able to stimulate channel activity to any significant extent (Fig. 2B and E).
At first sight, this result is in agreement with the proposal that metabolically generated changes in MgADP modulate channel activity: in other words, the channel no longer responds to metabolism because it cannot detect changes in MgADP levels. However, it is important to remember that mutations that abolish MgADP activation will also prevent the shift in the ATP concentration-response curve to higher [ATP]i produced by MgADP. Thus, the ATP sensitivity of the mutant channel in the cell will be much less than that of wild-type channels (millimolar range) and closer to that measured in the excised patch (micromolar range). Thus, it is possible that the lack of metabolic activation of Kir6.2/SUR1-KAKM channels simply reflects a greater ATP sensitivity, which keeps the channel closed even when ATP falls on metabolic inhibition.
To test this idea, we coexpressed wild-type or mutant SUR1 with a mutant form of Kir6.2 with reduced ATP sensitivity. The aim was to shift the ATP sensitivity of Kir6.2 to higher ATP concentrations and then determine whether SUR1 mutations that abolish MgADP activation of the KATP channel still prevent metabolic activation. If so, then changes in Mg-nucleotides sensed by SUR1 are the sole link between β-cell metabolism and KATP channel activity. However, if metabolic inhibition is able to activate the channel, then changes in ATP mediated via Kir6.2 may also contribute to metabolic regulation.
Mutation of residue K185 in Kir6.2 to aspartate causes a profound decrease in the ability of ATP to block the KATP channel: half-maximal block increased from ∼10 μmol/l to 1.9 mmol/l ATP (24). Consistent with this finding, oocytes expressing Kir6.2-K185D/SUR1 channels had large currents in control solution, which were further activated by metabolic poisoning (Fig. 2C and E).
We next coexpressed Kir6.2-K185D with SUR1-KAKM. Mutation of the Walker A lysines in both NBDs of SUR1 prevented channel activation by MgADP (Fig. 3A and B). These channels also exhibited smaller whole-cell currents in control solution than Kir6.2-K185D/SUR1 channels (P < 0.05) (Fig. 2D and E). The ATP sensitivity of Kir6.2-K185D/SUR1-KAKM channels, measured in the excised patch, was 1.99 ± 0.43 mmol/l (n = 4) (Fig. 3C), similar to that of Kir6.2-K185D/SUR1 (1.9 mmol/l) (24) (Fig. 3A and B). Thus, the difference in resting currents (i, Fig. 2E) must reflect the contribution of MgADP/MgATP to the regulation of KATP channel activity in control solution, and it is consistent with the idea that cytosolic Mg-nucleotides induce a significant decrease in the apparent ATP sensitivity of the channel in the cell.
If KATP channel activation on metabolic inhibition were to be mediated entirely by Mg-nucleotide interaction with SUR1, Kir6.2-K185D/SUR1-KAKM channels should not be activated by azide (because they are insensitive to MgADP). But as Fig. 2D and E shows, Kir6.2-K185D/SUR1-KAKM channels were in fact activated by azide. Thus, this increase in current (ii, Fig. 2E) must be mediated by the fall in [ATP]i, and sensed by Kir6.2. This is consistent with the observation that Kir6.2ΔC expressed in the absence of SUR1 (IC50 = 100–200 μmol/l) also shows a small activation on metabolic poisoning (18).
So why is activation of Kir6.2/SUR1-KAKM channels not observed on metabolic poisoning? We hypothesize that the enhanced ATP sensitivity of this channel in the cell, produced by the loss of Mg-nucleotide activation, is responsible and that the fall in [ATP]i produced by azide is no longer sufficient to activate the channel. In contrast, the much lower ATP sensitivity of Kir6.2-K185D ensures that even when Mg-nucleotide activation is abolished by the SUR1-KAKM mutation, the channel is able to respond to metabolically generated changes in ATP. It is important to recognize that the reduction in cellular ATP sensitivity associated with the SUR1-KAKM mutation is much greater than that seen in the excised patch, because of the presence of cytosolic MgADP.
Our experiments indicate that it is not possible to exclude the possibility that changes in [ATP]i couple β-cell metabolism to KATP channel closure or that Kir6.2 serves as a metabolic sensor. They are also consistent with the idea that cytosolic MgADP (or MgATP hydrolysis) shifts the ATP dose-response curve into a range in which Kir6.2 can respond to physiologically relevant changes in ATP. Changes in MgADP consequent on metabolism are probably too small to influence channel activity by displacing MgATP binding to the NBDs of SUR1 (see above). However, changes in the rate of MgATP hydrolysis might also play a role in coupling metabolism to KATP channel inhibition, as demonstrated in heart (28).
A role for Kir6.2 in metabolic sensing seems reasonable, given that the ATP sensitivity in the intact cell is considerably less than that of the excised patch (47). It also provides a rational explanation for the fact that a heterozygous Kir6.2 mutation (R201C), which produces a mere twofold decrease in ATP sensitivity in the inside-out patch, leads to loss of insulin secretion and permanent neonatal diabetes in humans (P. Proks, F.A., unpublished observations; see also ref. 5). It, too, is associated with an increase in resting current. Similar results have been reported for transgenic mice expressing Kir6.2 with reduced ATP sensitivity (7). A common polymorphism in Kir6.2 (E23K) is associated with an increased risk of type 2 diabetes (54), which has been attributed to a small decrease in the channel ATP sensitivity (55) although the mechanism remains controversial (56). Nevertheless, the marked effects on insulin secretion of Kir6.2 mutations, which produce only small changes in ATP sensitivity, argue for a role of Kir6.2 in metabolic sensing.
ROLE OF CREATINE AND ADENYLATE KINASE SHUTTLES
How are the changes in mitochondrial ATP transferred to the plasma membrane? In cardiac muscle, this is mediated by an intracellular phosphotransfer network that shuttles high energy–rich phosphates from the mitochondria to the plasma membrane without much change in [ATP]i (57). It seems plausible that a similar system exists in β-cells, with creatine kinase (CK) linking ATP generation to KATP channel closure and adenylate kinase (AK) regulating KATP channel opening. As proposed for the heart (57), in the microenvironment of the channel AK could convert AMP and ATP to ADP, promoting channel opening, whereas CK could catalyze the transfer of phosphate from PCr to ADP, producing creatine and ATP and, consequently, channel closure.
Recent studies indicate that the PCr concentration in islets increases on exposure to glucose (42). In addition, PCr reduces the ability of ADP to stimulate KATP channel activity in β-cells (42) (Fig. 4), suggesting that there may be a membrane-bound CK in the vicinity of the KATP channel. It will now be important to determine if CK is physically associated with the β-cell KATP channel, as is the case for cardiac channels (59). Likewise, the extent to which AK modulates KATP channel activity in β-cells requires further investigation.
CONCLUSIONS
It is apparent from this review that the metabolic regulation of the KATP channel is extremely complex. PPIs and LC-CoAs exert a tonic effect on the channel ATP, shifting the ATP dose-inhibition curve to higher ATP concentrations. Thus, they contribute to the difference in ATP sensitivity measured in excised patches and intact cells (40,43,47). However, changes in the concentrations of these compounds are probably not involved in modulating KATP channel activity in response to glucose. This role is played by adenine nucleotides. We propose that both Kir6.2 and SUR1 subunits participate in metabolic sensing, in a kind of molecular pas de deux. Their activity may be further modulated by additional factors that regulate the levels of nucleotides in the immediate environment of the channel. Thus, the KATP channel may be considered as part of a larger macromolecular complex that links metabolic events to electrical activity and ultimately insulin secretion.
A.T. and J.D. contributed equally to this work.
This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from Servier.
Article Information
We thank the Wellcome Trust, the European Union (GrowBeta), and the Royal Society for support. F.M.A. is the GlaxoSmithKline Research Professor of the Royal Society.